Clin2
NCT07590336Possibly a fitNot yet recruiting

Advanced imaging scan for liver cancer detection

Hepatocellular Carcinoma (HCC)

Part of Cancer, Digestive system clinical trials.

This study tests a new type of imaging scan (called 68Ga-NYM207 PET/CT) that may help doctors better find and understand liver cancer. You would receive the scan once to see if it helps doctors plan your treatment or monitor your cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
100 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are at least 18 years old
  • You have a liver mass scheduled for surgery or biopsy within the next month, OR you have a history of liver cancer with signs of recurrence or spread
  • You are willing to attend the study visit and follow the imaging procedure
  • You are not currently pregnant or nursing
  • You do not have severe claustrophobia (extreme fear of enclosed spaces)
  • You are not currently taking drugs that specifically target a protein called GPC3

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07677774Recruiting
GPC3-targeted PET/CT for detecting liver cancer

This study uses a special PET/CT scan that targets a protein (GPC3) found in liver cancer cells. The goal is to see how well it can detect or track liver cancer, whether it's newly diagnosed or has been treated before.

Xiamen, Fujian
NCT06746194Recruiting
PET scan to check treatment response in advanced liver cancer

This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.

Shanghai, Shanghai Municipality
NCT07178587Recruiting
New PET scan for liver and neuroendocrine tumors

This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.

Brest
NCT06735560Recruiting
PET scan with a tracer for liver, bile duct, or neuroendocrine tumors

This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.

Nantes
NCT06792097Not yet recruiting
Testing a new PET scan for liver cancer before RFA

This study tests a new PET scan (Ga-68 Dolacga) to see how well it images liver cancer before you have a standard heat treatment (radiofrequency ablation). The scan may help doctors plan your procedure more precisely.

NCT07144748Recruiting
New PET/CT scan for finding cancer

This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.

Beijing

Hear when a new Hepatocellular Carcinoma (HCC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.